Isosceles Pharmaceuticals

Isosceles Pharmaceuticals is a private, preclinical-stage biotech founded in 2019, targeting the massive and growing acute pain market with intravenous and intradermal formulations of synthetic cannabidiol. The company's strategy centers on bypassing first-pass metabolism via parenteral delivery to achieve fast onset and high bioavailability, positioning its candidates as potential alternatives to addictive opioids. Led by a team with extensive experience in pain product development, Isosceles is operating in a high-need area driven by the opioid epidemic and increasing surgical volumes, though it faces significant development and regulatory risks common to early-stage drug developers.

Novel parenteral (intravenous and intradermal) delivery systems for synthetic cannabinoids, designed to bypass first-pass metabolism for rapid onset, high bioavailability, and long-acting analgesia.

Isosceles competes in the crowded non-opioid analgesic space, facing competition from other cannabinoid developers, novel mechanism drugs (e.g., NaV1.7 inhibitors, NGF antibodies), and reformulations of existing non-opioid drugs. Its differentiation hinges on its parenteral delivery platform aiming for rapid onset, a key advantage in acute pain.